Jiro‘s Pick this week is bubblebath by Adam Danz.Adam is no stranger to File Exchange and File Exchange Pick of the Week. He is even more active on MATLAB Answers. In fact, this entry by... read more >>

Will‘s pick this week is progressbar by Steve Hoelzer. This is a File Exchange contribution that has been around since at least 2005. It has 76 downloads in the past 30 days and a 5 star rating... read more >>

KJ Apa and Britt Robertson in "I Still Believe" ; Credit: Lionsgate/I Still Believe (2020)

Larry Mantle and KPCC film critics Amy Nicholson and Wade Major review this weekend’s new movie releases.

• "I Still Believe" on VOD

• "Banana Split" on VOD 

• "Vivarium" on VOD

• "Resistance" on VOD

• "Vitalina Varela" on GrasshopperFilm.com

• "Uncorked" on Netflix

• "Dosed" on film's website

• "The Occupant" on Netflix

• "Tape" on VOD

• "There's Something In The Water" on Netflix

Guests:

Amy Nicholson, film critic for KPCC, film writer for The Guardian and host of the podcasts ‘Unspooled’ and the podcast miniseries “Zoom”; she tweets @TheAmyNicholson

Wade Major, film critic for KPCC and CineGods.com

This content is from Southern California Public Radio. View the original story at SCPR.org.

Talia Ryder and Théodore Pellerin in "Never Rarely Sometimes Always".
; Credit: Focus Features/Never Rarely Sometimes Always (2020)

Larry Mantle and KPCC film critics Lael Loewenstein, Peter Rainer and Christy Lemire review this weekend’s new movie releases and share their picks for the best movies and TV shows to binge, rewatch or see for the first time while you’re staying at home.

• "Never Rarely Sometimes" on VOD (for rent on Amazon Prime & FandangoNOW)

• "Bacurau" on virtual cinemas, including Laemmle's and Alamo Drafthouse

• "Slay The Dragon" on VOD, including iTunes

• "About A Teacher" on Amazon Prime Video

• "Dolphin Reef" on Disney+

• "Elephant" in Disney+

Guests:

Lael Loewenstein, KPCC film critic and film columnist for the Santa Monica Daily Press; she tweets @LAELLO

Peter Rainer, film critic for KPCC and the Christian Science Monitor

Christy Lemire, film critic for KPCC, RogerEbert.com and co-host of the ‘Breakfast All Day’ podcast; she tweets @christylemire

This content is from Southern California Public Radio. View the original story at SCPR.org.

Chris Hemsworth and Rudhraksh Jaiswal in Extraction.; Credit: Netflix/Extraction (2020)

Larry Mantle and KPCC film critics Christy Lemire, Angie Han and Wade Major review this weekend’s new movie releases on streaming and VOD platforms.

• "Extraction" on Netflix

• "Bad Education" on HBO

• "Circus Of Books" on Netflix

• "Why Don't You Just Die!" on VOD (iTunes, Amazon & Google Play)

• "Beastie Boys Story" on Apple TV+

• "Robert The Bruce" on VOD (iTunes, Amazon, FandangoNOW & Google Play)

• "1BR" on VOD (iTunes) & DVD

• "The True History Of The Kelly Gang" on VOD (iTunes, Vudu & Google Play)

Guests:

Angie Han, KPCC film critic and deputy entertainment editor at Mashable; she tweets @ajhan

Christy Lemire, film critic for KPCC, RogerEbert.com and co-host of the ‘Breakfast All Day’ podcast; she tweets @christylemire

Wade Major, film critic for KPCC and CineGods.com

This content is from Southern California Public Radio. View the original story at SCPR.org.

A new study has investigated the impacts of human activity on Antarctic Marine and Coastal. Alongside local effects of fishing, pollution and invasive alien species, global climate change is causing sea temperature rises and ocean acidification. Action is therefore needed at all levels to address these impacts.

4 awesome discoveries you probably didn't hear about this week -- Episode 31

4 awesome discoveries you probably didn't hear about this week -- Episode 32

Founder and Executive Chairman of Alibaba Group Jack Ma (L) attends the company's initial price offering (IPO) at the New York Stock Exchange on September 19, 2014 in New York City. ; Credit: Andrew Burton/Getty Images

Alibaba's stock is surging as the Chinese e-commerce powerhouse begins its first day trading as a public company.

The stock opened at $92.70 and nearly hit $100 on the New York Stock Exchange Friday, a gain of 46 percent from the initial $68 per share price set Thursday evening.

At Friday's opening price, the company is worth $228.5 billion, more than companies such as Amazon, Ebay and even Facebook.

Jubilant CEO Jack Ma stood on the NYSE trading floor Friday as eight Alibaba customers, including an American cherry farmer and a Chinese Olympian, rang the opening bell.

"We want to be bigger than Wal-Mart," Ma told CNBC shortly after the opening Bell. "We hope in 15 years people say this is a company like Microsoft, IBM, Wal-Mart, they changed, shaped the world."

On Thursday, Alibaba and the investment bankers arranging the initial public offering settled on a price of $68 per share. The company and its early investors raised $21.8 billion in the offering, which valued Alibaba at $168 billion in one of the world's biggest ever initial public offerings.

The company, which is trading under the symbol "BABA," has enjoyed a surge in U.S. popularity over the past two weeks as investors met with executives, including its colorful founder Jack Ma. As part of the so-called roadshow, would-be investors heard a sales pitch that centered on Alibaba's strong revenue growth and seemingly endless possibilities for expansion. Demand was so high that the company raised its offering price to $66 to $68 per share from $60 to $66 per share on Monday.

The main reason investors appear breathless about the 15-year old Alibaba: It offers an investment vehicle that taps into China's burgeoning middle-class.

Alibaba's Taobao, TMall and other platforms account for some 80 percent of Chinese online commerce. Most of Alibaba's 279 million active buyers visit the sites at least once a month on smartphones and other mobile devices, making the company attractive to investors as computing shifts away from laptop and desktop machines.

And the growth rate is not expected to mature anytime soon. Online spending by Chinese shoppers is forecast to triple from its 2011 size by 2015. Beyond that, Alibaba has said it plans to expand into emerging markets and eventually, Europe and the U.S.

"There are very few companies that are this big, grow this fast, and are this profitable," said Wedbush analyst Gil Luria.

Alibaba operates an online ecosystem that lets individuals and small businesses buy and sell. It doesn't directly sell anything, compete with its merchants, or hold inventory.

"The business model is really interesting. It's not just an eBay, it's not an Amazon, it's not a Paypal. It's all of that and much more," said Reena Aggarwal, a professor at Georgetown.

Like China's consumer and Internet market, Alibaba is still growing rapidly. The company's revenue in its latest quarter ending in June surged 46 percent from last year to $2.54 billion while its earnings climbed 60 percent to nearly $1.2 billion, after subtracting a one-time gain and certain other items.

In its last fiscal year ending March 31, Alibaba earned $3.7 billion, making it more profitable than eBay Inc. and Amazon.com Inc. combined. Amazon ended Thursday with a market value of about $150 billion while eBay's market value stood at $67 billion.

Alibaba, is based in Hangzhou in Eastern China, Ma's hometown. The company got started in 1999 when Ma and 17 friends developed a fledgling e-commerce company on the cusp of the Internet boom. Today, Alibaba's main platforms are its original business-to-business service Alibaba.com, consumer-to-consumer site Taobao and TMall, a place for brands to sell to consumers.

And while there's plenty of growth left in China, Ma has recently hinted about plans to expand beyond those borders.

"We hope to become a global company, so after we go public in the U.S., we will expand strongly in Europe and America," Ma said to a group of reporters in Kowloon on Monday.

Alibaba offered 320.1 million shares for a total offering size of $21.77 billion. Underwriters have a 30-day option to buy up to about 48 million more shares. That means the offering size could be as much as $25 billion

The IPO's fundraising handily eclipses the $16 billion Facebook raised in 2012, the most for a technology IPO. If all of its underwriters' options are exercised, it would also top the all-time IPO fundraising record of $22.1 billion set by the Agricultural Bank of China Ltd. in 2010.

Yahoo, which has been struggling to grow for years, made a windfall $8.28 billion by selling 121.7 million of is Alibaba shares. And founder Jack Ma sold 12.75 million shares worth $867 million.

Ron Struthers of Struthers' Resource Stock Report details the value proposition of Bam Bam Resources and its flagship prospect.

A rendering of he new stadium and complex to be built near the Forum in Inglewood was released by the Hollywood Park Land Company, Kroenke Group and Stockbridge Capital Group earlier this month.; Credit: Courtesy Hollywood Park Land Company

A measure that would allow an 80,000-seat NFL-caliber stadium to be built in Inglewood could be on that city’s ballot by this summer after developers submitted almost three times as many signatures than needed for a voter initiative.

“22,216 signatures were submitted to the city clerk today,” said Gerard McCallum, project manager with the Hollywood Park Land Company. “It was unbelievable. The response was more than we could have ever anticipated.”

Normally, before construction can begin on any project there has to be an environmental review, but that can take a long time and time is something in short supply for St. Louis Rams Owner Stan Kroenke and his plan to move the team to L.A.

“We would be going through another three year project process, and the current construction wouldn’t allow that,” said McCallum, referring to the redevelopment of 238 acres of the old Hollywood Park site that was permitted in 2009.

“If we were going to make any modifications, it would have to be approved this year,” said McCallum.

To speed things up, developers decided to bring the stadium project directly to Inglewood voters, which required 8,000 signatures.

Once the signatures are verified, Inglewood’s City Council will consider the measure, then developers hope a special election would take place before the start of the next NFL season.

McCallum says construction would begin whether the Rams or any other team decides to move here, though on Monday Kroenke made another move suggesting a return of the NFL to Los Angeles could be closer than it has been at any point during the last two decades, though not until after the 2015 season. From The St Louis Post-Dispatch:

Rams management sent a letter to regional officials on Monday afternoon. The letter said the team was converting its 30-year lease to an “annual tenancy,” effective April 1 and, “in the absence of intervening events,” extending through March 31, 2016.

The notice, which has long been expected, does two things:

• It allows owner Stan Kroenke to pull the team out of St. Louis as soon as 2016, because the Rams lease will now expire at the end of every season. The original lease was to expire in 2025.
• It also legally binds the Rams to play at the Edward Jones Dome next fall — a point on which many here were uncertain.

This content is from Southern California Public Radio. View the original story at SCPR.org.

Full Text:

The molecular mechanism used by many bacteria to kill neighboring cells has redundancy built into its genetic makeup, which could allow for the mechanism to be expressed in different environments, say researchers at Penn State and the University of Wisconsin-Madison. Their new study provides insights into the molecular mechanisms of competition among bacteria. "Many organisms, including humans, acquire bacteria from their environment," said Tim Miyashiro, a biochemist and molecular biologist at Penn State and the leader of the research team. "These bacteria can contribute to functions within the host organism, like how our gut bacteria help us digest food. We're interested in the interactions among bacteria cells, and between bacteria and their hosts, to better understand these mutually beneficial symbiotic relationships." Cells of the bioluminescent bacteria Vibrio fisheri take up residence in the light organ of newly hatched bobtail squid. At night, the bacteria produce a blue glow that researchers believe obscures a squid's silhouette and helps protect it from predators. The light organ has pockets, or crypts, in the squid's skin that provide nutrients and a safe environment for the bacteria. "When the squid hatches, it doesn't yet have any bacteria in its light organ," said Miyashiro. "But bacteria in the environment quickly colonize the squid's light organ." Some of these different bacteria strains can coexist, but others can't. "Microbial symbioses are essentially universal in animals, and are crucial to the health and development of both partners," says Irwin Forseth, a program director in the National Science Foundation's Division of Integrative Organismal Systems, which funded the research. "The results from this study highlight the role small genetic changes can play in microbe interactions. Increased understanding will allow us to better predict organisms' performance in changing environments."

Image credit: Andrew Cecere

4 awesome discoveries you probably didn't hear about this week -- Episode 32

A prolific ransomware gang vows to dial back its campaigns and spare healthcare organizations altogether during the COVID-19 crisis. It’s no cause for celebration.

The post The good, the bad and the plain ugly appeared first on WeLiveSecurity

If we can’t secure the supply chain, eventually everything else will break

The post What happens when the global supply chain breaks? appeared first on WeLiveSecurity

With World Backup Day upon us, we walk you through the ways to back up your iPhone or Android phone so that your personal information remains safe

The post Have you backed up your smartphone lately? appeared first on WeLiveSecurity

With Zoom – and Zoom-bombing – being all the rage, here’s why the app’s default password settings may be leaving the backdoor wide open

The post Ever needed a Zoom password? Probably not. But why not? appeared first on WeLiveSecurity

While in France, a citizen of Brazil who resides in California books a bungee jump in New Zealand. Is it a leap of faith into the unknown, for both the operator and the thrill-seeker?

The post Is “global privacy” an oxymoron? appeared first on WeLiveSecurity

The tool, which comes after a similar effort by Google, looks at how people’s traveling behavior has changed since the start of the pandemic

The post Apple releases mobility data to help combat COVID‑19 appeared first on WeLiveSecurity

Source: Streetwise Reports   04/22/2020

In an April 19 research note, ROTH Capital Partners analyst Yasmeen Rahimi reported that the Biomedical Advanced Research and Development Authority (BARDA) awarded Moderna Inc. (MRNA:NASDAQ) $483 million in funding, in part for development of its COVID-19 vaccine, mRNA-1273.

Rahimi discussed how Massachusetts-based Moderna will use the funds, which will be provided in tranches to reach certain milestones.

Half of the $483 million award will be used to help cover clinical development costs of mRNA-1273, from trial operations to the filing of a biologics license application.

Currently, the vaccine is in Phase 1 in the clinic. Recently, the biopharma decided to add to the study a cohort of patients aged 51 years and up, which "will be key for demonstrating mRNA-1273's safety and immunogenicity in this vulnerable population," Rahimi noted.

The analyst explained that for mRNA-1273 to advance to Phase 2, the results from Phase 1 must be optimal. The data must demonstrate the vaccine is safe and tolerable. They must show that the vaccine produced a sufficient number of neutralizing antibodies, crucial for stopping viral replication and proving the vaccine's method of action. Phase 1 safety data from the group aged 18–55 years are expected in spring followed by immunogenicity results, likely in mid-July or early August.

Rahimi relayed that as soon as safety data are available, Moderna plans to launch a Phase 2 study of mRNA-1273 rather than wait for the remaining results to become available, according to CEO Stéphane Bancel.

"Pending favorable safety data from Phase 1, we point out that a potential Phase 2 study would enroll hundreds of patients, and that the BARDA funding could potentially allow Moderna to pursue trials in patient populations who are at greater risk, such as patients who have underlying comorbidities, those who are overweight and patients with cancer," commented Rahimi.

Moderna will spend the second half of the $483 million BARDA funding on the engineering and optimization work required to scale up the manufacturing of its messenger RNA (mRNA).

"With the current focus on SARS-CoV-2 and mRNA-1273, Moderna was now able to present BARDA its strategic plans (amount, time and people) of how to be ready for commercial launch," wrote Rahimi. "This preparation was likely helpful in expediting discussions with BARDA and awarding of the grant."

Also regarding mRNA production, Ginkgo Bioworks, a company with expertise in organism biology and genetically engineering bacteria to replace certain industrial applications, is helping Moderna optimize certain parts of the process.

Rahimi, who is closely tracking COVID-19 data, highlighted that April 18 was the first day in five on which the daily death tally, 1,867, was less than that predicted by Dr. Christopher Murray's model, 2,194.

ROTH has a Buy rating on Moderna.

Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.

Disclosures from ROTH Capital Partners, Moderna Inc., Company Note, April 19, 2020

Regulation Analyst Certification ("Reg AC"): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Within the last twelve months, ROTH has received compensation for investment banking services from Moderna, Inc.

ROTH makes a market in shares of Moderna, Inc. and as such, buys and sells from customers on a principal basis.

Within the last twelve months, ROTH has managed or co-managed a public offering for Moderna, Inc.

ROTH Capital Partners, LLC expects to receive or intends to seek compensation for investment banking or other business relationships with the covered companies mentioned in this report in the next three months.

( Companies Mentioned: MRNA:NASDAQ, )

Source: Streetwise Reports   05/04/2020

Stemline Therapeutics Inc. (STML:NASDAQ), which is focused on developing and commercializing novel oncology therapeutics, today announced that it has entered into a definitive agreement to be acquired by private Italian pharmaceutical and diagnostics company Menarini Group in a transaction valued up to $677 million.

The companies advised that the transaction has already been unanimously approved by both companies' Boards of Directors and that the transaction is expected to close in Q2/20 subject to customary closing conditions, regulatory approvals and a tender of at least 50% of the outstanding Stemline shares by shareholders. Menarini stated that it plans to fund the purchase by using existing cash resources.

The firms outlined that purchase details and advised that "under the terms of the agreement, a wholly owned subsidiary of the Menarini Group will commence a tender offer for all outstanding shares of Stemline, whereby Stemline shareholders will be offered a total potential consideration of $12.50 per share, consisting of an upfront payment of $11.50 in cash and one non-tradeable Contingent Value Right (CVR) that will entitle each holder to an additional $1.00 in cash per share upon completion of the first sale of ELZONRIS in any EU5 country after European Commission approval."

The report explained that ELZONRIS is a novel targeted therapy directed to the interleukin-3 (IL-3) receptor-α (CD123) and was developed by Stemline for treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adult and pediatric patients. The firm stated that the U.S. Food and Drug Administration (FDA) approved that drug in the U.S. in December 2018. A marketing authorization application (MAA) has already been submitted and is presently under review by the European Medicines Agency. Post acquisition, Menarini expects to obtain approvals and expand distribution of ELZONRIS to Europe and emerging markets.

Stemline Therapeutics' Chairman, CEO and Founder Ivan Bergstein, M.D., commented, "Joining Menarini represents a unique opportunity for Stemline to advance the commercialization of ELZONRIS across the globe and to accelerate the development of our pipeline of oncology assets. ...We are excited to be combining with a like-minded organization in Menarini, in a transaction that will deliver immediate and significant cash value to our shareholders, while also allowing our shareholders to participate in the future upside of ELZONRIS's European launch."

Elcin Barker Ergun, CEO of Menarini Group, remarked, "Stemline is an excellent fit for Menarini, enabling us to expand our presence in the U.S. with an established biopharmaceutical company focused on developing oncology therapeutics. Through this acquisition, we will continue to strengthen our portfolio and pipeline of oncology assets and deliver novel therapies around the world."

The company described BPDCN, formerly blastic NK-cell lymphoma, as "an aggressive hematologic malignancy, often with cutaneous manifestations, with historically poor outcomes which typically presents in the bone marrow and/or skin and may also involve lymph nodes and viscera."

Stemline Therapeutics is a commercial-stage biopharmaceutical company headquartered in New York that develops and markets oncology therapeutics. The firm stated that its "ELZONRIS^® (tagraxofusp) is a targeted therapy directed to CD123 and is FDA-approved and commercially available in the U.S. for the treatment of adult and pediatric patients, two years and older, with BPDCN." Stemline noted that ELZONRIS is also being currently being evaluated in clinical studies for other indications including chronic myelomonocytic leukemia, myelofibrosis and acute myeloid leukemia.

The Menarini Group is an international pharmaceutical company based in Italy which operates and sells its products in more than 100 countries. The company stated that it has $4.2 billion in sales annually. The company's medicines address many areas of illnesses including cardiovascular, gastroenterology, metabolic, infectious diseases and anti-inflammatory/analgesic therapeutic areas and oncology.

Stemline Therapeutics began the day with a market capitalization of around $249.2 million with approximately 54.27 million shares outstanding and a short interest of about 11.3%. STML shares opened nearly 150% higher today at $11.81 (+$7.06, +148.63%) over Friday's closing price of $4.75. The stock has traded today between $1.81 and $12.35 per share and is currently trading at $12.10 (+$7.35, +154.74%).

Disclosure:
1) Stephen Hytha compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. He or members of his household own securities of the following companies mentioned in the article: None. He or members of his household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
6) This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

( Companies Mentioned: STML:NASDAQ, )

My new book LOSERTHINK, available now on Amazon https://tinyurl.com/rqmjc2a Content: Is the record unambiguous…it was a coup attempt? Mind-readers confirm, Schiff is panicked Tim Graham’s visual writing style Ahmaud Arbery shooting The Plandemic video If you would like to enjoy this same content plus bonus content from Scott Adams, including micro-lessons on lots of useful […]

The post Episode 960 Scott Adams: Fake News, Bad Math, Bad Mind-Reading, Bad Behavior in the News appeared first on Scott Adams' Blog.

Urban planning policy has had a powerful influence on the amount of green space in cities, according to a recent UK study. It found that a change in planning policy in 2000 led to a decline in urban green space in nine cities between 2001 and 2006, although the amount of green space in all but one of the cities studied has increased overall since 1991.

A recent study has assessed the lifecycle environmental impact during the production and use phase of three battery types for plug-in hybrid (PHEV) and full performance battery electric vehicles (BEV). The study indicates that newer lithium-ion (Li-ion) technologies outperform current nickel-metal hydride (NiMH) batteries and identifies processes contributing to 13 environmental impacts

Urban vegetation could have been overlooked as valuable above-ground carbon storage, according to researchers. They estimated that 231,521 tonnes of carbon were stored in above-ground vegetation in a UK city, the majority of which (97 per cent) in trees. This was 10 times the amount estimated from national figures for the same city area.

A new Spanish study has highlighted current developments in the tourism sector that have significant implications for water supply and demand, but are barely addressed in recent land use policies. The findings indicate that any tourist destination that is to follow the ???quality tourist??? model will have an increased water demand in domestic residential areas, which is one of the biggest threats to sustainable water management.

A new study highlights the positive effects of plants and trees in cities. Urban green areas provide shade and reduce temperature fluctuations, bringing average temperatures down, while covering roofs with plants, rather than black roofs, reduces the energy required to heat and cool buildings.

Hypoxia (low levels of oxygen) is widespread in the coastal waters of the Baltic Sea, according to recently published research. The trend of increasing hypoxia since the 1950 is alarming, although improvements can be seen in some areas as a result of measures to reduce inputs of organic material.

For the first time, researchers have applied a carbon footprint analysis to calculate carbon sequestration by an urban green space. Their results indicate that urban green space can act as a carbon sink, but its design and maintenance influence the amount stored.

A new study has investigated the possibility of a regional industrial symbiosis of metal industries across the Sweden-Finland border. The analysis suggests that it is technologically feasible, but that regulatory support may be inefficient, particularly with respect to changing the status of a waste product to a by-product.

A new tool has been developed, with input from the public, to measure and compare the quality of green spaces in urban areas. A UK case study suggests that litter and vandalism are among the factors most likely to prevent local residents from using and benefiting from green spaces.

Global air quality will significantly deteriorate by 2050 unless further steps are taken to cut current emissions from human activities, according to recent research. Most people around the world will be affected by worsening air quality with hotspots of particularly poor air occurring in China, northern India and the Middle East.